ArticleAnnals of clinical and translational neurology2026
CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectiveProgression independent of relapse activity is a major determinant of long-term disability in multiple sclerosis, but its immunopathologic basis remains incompletely understood. We investigated whether relapse-independent progression in radiologically stable relapsing-remitting multiple sclerosis is associated with distinct cerebrospinal fluid inflammatory profiles and whether cytokine-network features provide information beyond single-mediator levels.
methodsIn this prospective observational cohort study, baseline cerebrospinal fluid cytokine and chemokine profiling was performed in 346 RRMS patients, 61 primary progressive multiple sclerosis (PPMS) patients, and 196 neurological controls without inflammatory or neurodegenerative central nervous system disease. After 2-year clinical and MRI follow-up, 37 RRMS patients with clinical relapse and/or MRI activity were excluded, leaving 309 relapse-free and MRI-stable RRMS patients classified as stable RRMS (n = 241) or RRMS with PIRMA (n = 68). Cytokines were analyzed using two-part hurdle models, cytokine interactomes, and machine-learning classifiers.
resultsQuantitative cytokine analyses distinguished multiple sclerosis from controls but showed substantial overlap across multiple sclerosis phenotypes. RRMS with PIRMA showed higher cerebrospinal fluid levels of tumor necrosis factor-α, interleukin-17, and RANTES than stable RRMS. Network analyses showed a more integrated cytokine interactome in RRMS with PIRMA. The network-level model best distinguished RRMS with PIRMA from stable RRMS, with an area under the curve of 0.86, sensitivity of 77%, and specificity of 76%.
interpretationRelapse-independent progression in multiple sclerosis is associated with selective cytokine changes and broader reorganization of inflammatory network architecture, supporting cerebrospinal fluid cytokine interactome profiling as a translational approach to immune stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.